Ceftazidime–Avibactam in Multidrug-Resistant Klebsiella spp. Infections: Is Monotherapy as Effective as Combination Therapy?
Antibiotics · 25.01.2026 · 15 (2) · 116
DOI: 10.3390/antibiotics15020116 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibiotics, online erschienen am 25.01.2026. Verfasst von Rukiyye Bulut und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Clinical Microbiology, Necmettin Erbakan University Faculty of Medicine, Konya 42080, Türkiye. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Carbapenem-resistant Klebsiella spp. (CRK) causes healthcare-associated infections with high mortality. This study evaluated the clinical outcomes of ceftazidime–avibactam (CZA) therapy in CRK infections.
Methods
Patients hospitalized in a tertiary care hospital in Türkiye between June 2021 and December 2022 with CRK-positive cultures, CZA susceptibility, and ≥72 h of CZA treatment were retrospectively analyzed.
Results
Ninety-nine patients (61.6% male; mean age 63.7 ± 17.5 years) were included, 89.9% of whom were treated in the intensive care unit (ICU). Hypertension (29.3%), diabetes (28.3%), and malignancy (26.3%) were the most frequent comorbidities. The main infection types were bloodstream infection (56.6%) and ventilator-associated pneumonia (29.3%). CZA was used as monotherapy in 49.5%, and in combination in 50.5% of cases. The mean treatment duration was 13.2 ± 6.3 days. Clinical improvement occurred at 3.4 ± 1.2 days and microbiological eradication at 4.7 ± 2.1 days. Treatment success was achieved in 76.8% of patients, while 30- and 90-day mortality rates were 48.5% and 72.7%, respectively. Only treatment duration significantly affected clinical outcome (p < 0.001).
Conclusions
CZA demonstrates favorable outcomes in CRK infections, with no significant difference between monotherapy and combination therapy. These findings support the use of CZA as an effective treatment option for severe CRK infections in real-world clinical settings and may help guide antimicrobial stewardship strategies in high-risk hospitalized patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Infectious Diseases and Clinical Microbiology, Necmettin Erbakan University Faculty of Medicine, Konya 42080, Türkiye.
- Department of Infectious Diseases and Clinical Microbiology, Konya City Hospital, Konya 42090, Türkiye.
ORCID-Profile: Rukiyye Bulut, İbrahim Erayman, Bahar Kandemir, Pınar Belviranlı Keskin
Zitieren
APA
Bulut, R., Erayman, İ., Kandemir, B., & Keskin, P. B. (2026). Ceftazidime–Avibactam in Multidrug-Resistant Klebsiella spp. Infections: Is Monotherapy as Effective as Combination Therapy?. Antibiotics, 15(2), 116. https://doi.org/10.3390/antibiotics15020116
Vancouver
Bulut R, Erayman İ, Kandemir B, Keskin PB. Ceftazidime–Avibactam in Multidrug-Resistant Klebsiella spp. Infections: Is Monotherapy as Effective as Combination Therapy?. Antibiotics. 2026;15(2):116. doi:10.3390/antibiotics15020116
BibTeX
@article{Bulut2026,
author = {Bulut, Rukiyye and Erayman, İbrahim and Kandemir, Bahar and Keskin, Pınar Belviranlı},
title = {Ceftazidime–Avibactam in Multidrug-Resistant Klebsiella spp. Infections: Is Monotherapy as Effective as Combination Therapy?},
journal = {Antibiotics},
year = {2026},
volume = {15},
number = {2},
pages = {116},
doi = {10.3390/antibiotics15020116}
}
EUVIMED